Clinical outcome of thymic lymphoepithelioma‑like carcinoma: Case report of a 14‑year‑old male

Sekihara,Kuniko; Okuma,Yusuke; Kawamoto,Hiroshi; Hosomi,Yukio

doi:10.3892/ol.2014.2475

Clinical outcome of thymic lymphoepithelioma‑like carcinoma: Case report of a 14‑year‑old male

Authors:
- Kuniko Sekihara
- Yusuke Okuma
- Hiroshi Kawamoto
- Yukio Hosomi
View Affiliations

Affiliations: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo 113‑8677, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo 113‑8677, Japan, Department of Pediatrics, National Cancer Center Hospital, Tokyo 104‑0045, Japan
Published online on: August 22, 2014 https://doi.org/10.3892/ol.2014.2475
Pages: 2183-2186

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymic carcinoma is a rare type of cancer, which arises from the thymic epithelium and accounts for ~1‑4% of anterior mediastinal tumors in the USA. It rarely occurs in children, and is rarer among adults. Thymic lymphoepithelioma‑like carcinoma (LELC) is an uncommon subtype of thymic carcinoma in children, however, it is one of the common histological subtypes of thymic carcinoma in adults. In the present study, a 14‑year‑old male patient presented to the Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital (Tokoyo, Japan) with chest pain due to a large anterior mediastinal mass. The patient was histologically diagnosed with thymic LELC via a needle biopsy specimen, which was obtained from the primary site and indicated the Epstein‑Barr virus infection, whose markers are also associated with oncogenesis. Immunohistochemical analysis demonstrated positive staining for keratin (AE1/AE3), epithelial membrane antigen, and latent membrane protein‑1 and negative staining for cluster of differentiation 5. Thus, the patient was diagnosed with metastatic thymic LELC. First‑line chemotherapy comprising of a cisplatin‑ and adriamycin‑based chemotherapy regimen achieved a partial response, however, the patient succumbed within 10 months of the initial diagnosis due to rapid disease progression and refractory to subsequent cycles of chemotherapy. Thus, the current study, as well as previously reported cases, demonstrates that pediatric patients with thymic LELC continue to have a poor prognosis.

View Figures

View References

1	Engels EA and Pfeiffer RM: Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 105:546–551. 2003.
2	Rare Cancers Europe. http://www.rarecancerseurope.org/About-Rare-Cancers. Accessed August 12, 2014
3	Rosai J: Histological typing of tumours of the thymus. World Health Organization International histological classification of tumours Berlin: Springer-Verlag; pp. 5–15. 1999
4	Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: Tumours of the thymus. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: pp. 145–247. 2004
5	Wick MR, Scheithauer BW and Dines DE: Thymic neoplasia in two male siblings. Mayo Clin Proc. 57:653–656. 1982.
6	Marino M and Müller-Hermelink HK: Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch A Pathol Anat Histopathol. 407:119–149. 1985.
7	Fujii T, Kawai T, Saito K, et al: EBER-1 expression in thymic carcinoma. Acta Pathol Jpn. 43:107–110. 1993.
8	Ilhan I, Kutluk T, Göğüş S, Besim A and Büyükpamukçu M: Hypertrophic pulmonary osteoarthropathy in a child with thymic carcinoma: an unusual presentation in childhood. Med Pediatr Oncol. 23:140–143. 1994.
9	Niehues T, Harms D, Jürgens H and Göbel U: Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment. Med Pediatr Oncol. 26:419–424. 1996.
10	Stéphan JL, Galambrun C, Boucheron S, et al: Epstein-Barr virus - positive undifferentiated thymic carcinoma in a 12-year-old white girl. J Pediatr Hematol Oncol. 22:162–166. 2000.
11	Di Cataldo A, Villari L, Milone P, et al: Thymic carcinoma, systemic lupus erythematosus, and hypertrophic pulmonary osteoarthropathy in an 11-year-old boy: a novel association. Pediatr Hematol Oncol. 17:701–706. 2000.
12	Yaris N, Nas Y, Cobanoglu U and Yavuz MN: Thymic carcinoma in children. Pediatr Blood Cancer. 47:224–227. 2006.
13	Hsueh C, Kuo TT, Tsang NM, et al: Thymic lymphoepitheliomalike carcinoma in children: clinicopathologic features and molecular analysis. J Pediatr Hematol Oncol. 28:785–790. 2006.
14	Tacyildiz N, Ugur H, Yavuz G, et al: The coexistence of thymic carcinoma and multiple granulomas in a Turkish child. Pediatr Hematol Oncol. 24:301–307. 2007.
15	Kiliś-Pstrusińska K, Medyńska A, Zwolińska D and Dobaczewski G: Lymphoepithelioma-like thymic carcinoma in a 16-year-old boy with nephrotic syndrome - a case report. Pediatr Nephrol. 23:1001–1003. 2008.
16	Ettinger DS, Riely GJ, Akerley W, et al: National Comprehensive Cancer Network: Thymomas and thymic carcinomas: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 11:562–576. 2013.
17	Kunitoh H, Tamura T, Shibata T, et al: A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer. 101:1549–1554. 2009.
18	Okuma Y, Hosomi Y, Takagi Y, et al: Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer. 80:75–80. 2013.
19	Masaoka A: Staging system of thymoma. J Thorac Oncol. 5(10 Suppl 4): S304–S312. 2010.
20	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
21	Shimosato Y, Kameya T, Nagai K and Suemasu K: Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol. 1:109–121. 1977.
22	Okuma Y, Shimokawa T, Takagi Y, et al: S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer. 70:357–363. 2010.
23	Komatsu Y, Koizumi T, Tanabe T, et al: Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma - three cases. Anticancer Res. 26:4851–4855. 2006.
24	Wu TC and Kuo TT: Study of Epstein-Barr virus early RNA 1 (EBER1) expression by in situ hybridization in thymic epithelial tumors of Chinese patients in Taiwan. Hum Pathol. 24:235–238. 1993.
25	Chen FF, Yan JJ, Lai WW, Jin YT and Su IJ: Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated “lymphoepithelioma-like” carcinoma as a distinct entity with better prognosis. Cancer. 82:2334–2342. 1998.
26	Chalabreysse L, Etienne-Mastroianni B, Adeleine P, et al: Thymic carcinoma: a clinicopathological and immunohistological study of 19 cases. Histopathology. 44:367–374. 2004.
27	Ettinger DS, Riely GJ, Akerley W, et al: Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 11:562–576. 2013.
28	Agatsuma T, Koizumi T, Kanda S, et al: Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol. 6:2130–2134. 2011.